RS64584B1 - Konstruisani polipeptidi koji se vezuju za transferinski receptor - Google Patents
Konstruisani polipeptidi koji se vezuju za transferinski receptorInfo
- Publication number
- RS64584B1 RS64584B1 RS20230817A RSP20230817A RS64584B1 RS 64584 B1 RS64584 B1 RS 64584B1 RS 20230817 A RS20230817 A RS 20230817A RS P20230817 A RSP20230817 A RS P20230817A RS 64584 B1 RS64584 B1 RS 64584B1
- Authority
- RS
- Serbia
- Prior art keywords
- receptor binding
- transferrin receptor
- binding polypeptides
- engineered transferrin
- engineered
- Prior art date
Links
- 102000007238 Transferrin Receptors Human genes 0.000 title 1
- 108010033576 Transferrin Receptors Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762543658P | 2017-08-10 | 2017-08-10 | |
US201762583314P | 2017-11-08 | 2017-11-08 | |
PCT/US2018/018371 WO2018152326A1 (en) | 2017-02-17 | 2018-02-15 | Engineered transferrin receptor binding polypeptides |
PCT/US2018/046199 WO2019032955A1 (en) | 2017-08-10 | 2018-08-10 | MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES |
EP18756531.2A EP3665192B1 (en) | 2017-08-10 | 2018-08-10 | Engineered transferrin receptor binding polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
RS64584B1 true RS64584B1 (sr) | 2023-10-31 |
Family
ID=65272509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20230817A RS64584B1 (sr) | 2017-08-10 | 2018-08-10 | Konstruisani polipeptidi koji se vezuju za transferinski receptor |
Country Status (18)
Country | Link |
---|---|
US (4) | US20200369746A1 (sr) |
EP (2) | EP3665192B1 (sr) |
JP (3) | JP7280241B2 (sr) |
CN (2) | CN111148757B (sr) |
CA (2) | CA3072051A1 (sr) |
DK (1) | DK3665192T3 (sr) |
ES (1) | ES2956062T3 (sr) |
FI (1) | FI3665192T3 (sr) |
HR (1) | HRP20231118T1 (sr) |
HU (1) | HUE063021T2 (sr) |
LT (1) | LT3665192T (sr) |
MD (1) | MD3665192T2 (sr) |
PL (1) | PL3665192T3 (sr) |
PT (1) | PT3665192T (sr) |
RS (1) | RS64584B1 (sr) |
SI (1) | SI3665192T1 (sr) |
TW (1) | TWI821197B (sr) |
WO (2) | WO2019032955A1 (sr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20191551A1 (es) | 2017-02-17 | 2019-10-24 | Denali Therapeutics Inc | Polipeptidos de union al receptor de transferrina disenados |
TW201925236A (zh) | 2017-10-02 | 2019-07-01 | 美商戴納立製藥公司 | 包含酶替代療法酶之融合蛋白 |
IL293994A (en) | 2019-12-23 | 2022-08-01 | Denali Therapeutics Inc | Variants of progranulin, preparations containing them and their uses |
KR20220131246A (ko) * | 2020-01-13 | 2022-09-27 | 데날리 테라퓨틱스 인크. | 항-trem2 항체 및 이의 사용 방법 |
KR20220156526A (ko) * | 2020-02-19 | 2022-11-25 | 데날리 테라퓨틱스 인크. | 조작된 항-her2 이중특이성 단백질 |
MX2023004335A (es) | 2020-10-14 | 2023-05-04 | Denali Therapeutics Inc | Proteinas de fusion que comprenden enzimas sulfoglucosamina sulfohidrolasa y metodos de estas. |
EP4396231A1 (en) | 2021-09-01 | 2024-07-10 | Biogen MA Inc. | Anti-transferrin receptor antibodies and uses thereof |
WO2024026494A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Viral particles retargeted to transferrin receptor 1 |
WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
US20240052051A1 (en) | 2022-07-29 | 2024-02-15 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:payload fusions and methods of use thereof |
WO2024026488A2 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a modified transferrin receptor locus |
WO2024130116A2 (en) * | 2022-12-16 | 2024-06-20 | Denali Therapeutics Inc. | Methods and compositions related to engineered transferrin receptor‑binding molecules |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001016181A2 (en) * | 1999-08-30 | 2001-03-08 | New York University School Of Medicine | Crystal structures of domains of receptor protein tyrosine kinases and their ligands |
ES2354653T3 (es) * | 2006-08-01 | 2011-03-16 | Pieris Ag | Muteínas de lipocalina lacrimal y procedimientos para obtener las mismas. |
KR102188544B1 (ko) * | 2010-11-30 | 2020-12-08 | 제넨테크, 인크. | 저친화도 혈액-뇌 장벽 수용체 항체 및 그의 용도 |
EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
MX367126B (es) * | 2012-08-29 | 2019-08-06 | Hoffmann La Roche | Transporte para atravesar la barrera hematoencefálica. |
EP4324480A3 (en) * | 2013-05-20 | 2024-05-08 | F. Hoffmann-La Roche AG | Anti-transferrin receptor antibodies and methods of use |
BR112016015589A2 (pt) * | 2014-01-06 | 2017-10-31 | Hoffmann La Roche | módulos de trânsito monovalentes para a barreira hematoencefálica |
SG11201609274SA (en) * | 2014-05-22 | 2016-12-29 | Pieris Pharmaceuticals Gmbh | Novel specific-binding polypeptides and uses thereof |
EP3218411B1 (en) * | 2014-11-14 | 2022-01-12 | Ossianix, Inc. | Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use |
EP3221362B1 (en) | 2014-11-19 | 2019-07-24 | F.Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies and methods of use |
US11008403B2 (en) * | 2014-11-19 | 2021-05-18 | Genentech, Inc. | Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use |
WO2016207240A1 (en) * | 2015-06-24 | 2016-12-29 | F. Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
US10457717B2 (en) * | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
-
2018
- 2018-08-10 FI FIEP18756531.2T patent/FI3665192T3/fi active
- 2018-08-10 JP JP2020506964A patent/JP7280241B2/ja active Active
- 2018-08-10 WO PCT/US2018/046199 patent/WO2019032955A1/en active Application Filing
- 2018-08-10 TW TW107128067A patent/TWI821197B/zh active
- 2018-08-10 WO PCT/US2018/046337 patent/WO2019033046A1/en unknown
- 2018-08-10 CN CN201880063660.0A patent/CN111148757B/zh active Active
- 2018-08-10 JP JP2020507090A patent/JP2020530465A/ja active Pending
- 2018-08-10 HR HRP20231118TT patent/HRP20231118T1/hr unknown
- 2018-08-10 DK DK18756531.2T patent/DK3665192T3/da active
- 2018-08-10 RS RS20230817A patent/RS64584B1/sr unknown
- 2018-08-10 EP EP18756531.2A patent/EP3665192B1/en active Active
- 2018-08-10 SI SI201830986T patent/SI3665192T1/sl unknown
- 2018-08-10 MD MDE20200637T patent/MD3665192T2/ro unknown
- 2018-08-10 HU HUE18756531A patent/HUE063021T2/hu unknown
- 2018-08-10 EP EP18843180.3A patent/EP3665194A4/en active Pending
- 2018-08-10 CN CN201880053177.4A patent/CN111094336A/zh active Pending
- 2018-08-10 ES ES18756531T patent/ES2956062T3/es active Active
- 2018-08-10 PT PT187565312T patent/PT3665192T/pt unknown
- 2018-08-10 LT LTEPPCT/US2018/046199T patent/LT3665192T/lt unknown
- 2018-08-10 CA CA3072051A patent/CA3072051A1/en active Pending
- 2018-08-10 CA CA3072035A patent/CA3072035A1/en active Pending
- 2018-08-10 PL PL18756531.2T patent/PL3665192T3/pl unknown
-
2020
- 2020-02-05 US US16/782,669 patent/US20200369746A1/en not_active Abandoned
- 2020-02-05 US US16/782,984 patent/US20200289627A1/en not_active Abandoned
-
2023
- 2023-02-08 US US18/166,223 patent/US20230381286A1/en active Pending
- 2023-06-30 JP JP2023107814A patent/JP2023123757A/ja active Pending
- 2023-09-08 US US18/464,025 patent/US20240024432A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3665192A1 (en) | 2020-06-17 |
JP2020530465A (ja) | 2020-10-22 |
WO2019032955A1 (en) | 2019-02-14 |
US20200369746A1 (en) | 2020-11-26 |
JP2020530293A (ja) | 2020-10-22 |
US20230381286A1 (en) | 2023-11-30 |
TWI821197B (zh) | 2023-11-11 |
ES2956062T3 (es) | 2023-12-12 |
EP3665192B1 (en) | 2023-07-12 |
CN111148757B (zh) | 2024-06-21 |
US20200289627A1 (en) | 2020-09-17 |
LT3665192T (lt) | 2023-10-25 |
CN111148757A (zh) | 2020-05-12 |
CA3072035A1 (en) | 2019-02-14 |
HUE063021T2 (hu) | 2023-12-28 |
FI3665192T3 (fi) | 2023-09-28 |
EP3665194A1 (en) | 2020-06-17 |
DK3665192T3 (da) | 2023-10-09 |
JP7280241B2 (ja) | 2023-05-23 |
JP2023123757A (ja) | 2023-09-05 |
TW201920278A (zh) | 2019-06-01 |
SI3665192T1 (sl) | 2023-11-30 |
MD3665192T2 (ro) | 2023-12-31 |
CA3072051A1 (en) | 2019-02-14 |
EP3665194A4 (en) | 2021-07-07 |
PT3665192T (pt) | 2023-09-25 |
US20240024432A1 (en) | 2024-01-25 |
PL3665192T3 (pl) | 2023-11-27 |
HRP20231118T1 (hr) | 2023-12-22 |
WO2019033046A1 (en) | 2019-02-14 |
CN111094336A (zh) | 2020-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL268660A (en) | Polypeptides that bind to a transgenic transferrin receptor | |
PL3665192T3 (pl) | Konstruowane polipeptydy wiążące receptory transferyny | |
HK1251480A1 (zh) | Cd3結合多肽 | |
IL272643A (en) | Binders | |
ZA201906358B (en) | Improved antigen binding receptors | |
IL274926A (en) | Pyrazolopyrimidines with activity against respiratory syncytial virus | |
IL270969A (en) | Aggrecan-binding immunoglobulins | |
EP3625300C0 (en) | ADHESIVES | |
IL268288A (en) | Binders | |
IL270949A (en) | A protease and a polypeptide that binds to O-glycoproteins | |
GB201707139D0 (en) | Polypeptides | |
IL268360A (en) | Engineered concrete binding compound | |
GB201615588D0 (en) | TSLP Binding Proteins | |
IL269477A (en) | Polypeptides that bind to IL-1R-1 | |
GB201702069D0 (en) | Binding polypeptides | |
GB201801959D0 (en) | Binding polypeptides | |
IL266419A (en) | Binding peptides | |
GB201715149D0 (en) | IL-ß binding antibody | |
GB201901704D0 (en) | Binding polypeptides | |
GB201717958D0 (en) | Novel polypeptides | |
GB201713298D0 (en) | Binding agents | |
GB201713296D0 (en) | Binding agents | |
GB201701351D0 (en) | Binding agents | |
GB201618186D0 (en) | Binding members | |
GB201403306D0 (en) | Binding Polypeptides |